Clinical trials: Liver Tumour
Carcinoma, Hepatocellular
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
The investigators propose in this trial to test a hepatic chemotherapy, consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol, lipid vector, without embolization in the treatment of…
- Trial name
- LIDA-BII (NCT03727633)
- Testing
- Idarubicin and Lipiodol
- Where
- 4 sites in France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Montpellier
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Hepatocellular Carcinoma (HCC)
AI Multitask Model for HCC Treatment
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma.
- Trial name
- NCT07157085
- Testing
- Comprehensive treatment
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Sun Yat-sen University
Liver Cancer, Adult
Liver Function Investigation With SPECT
This is a Phase 1 pilot study to assess feasibility and utility of 99mTc-mebrofenin hepatobiliary scintigraphy for measurement of functional liver change due to radiotherapy.
- Trial name
- LiverINSPECT (NCT02967848)
- Testing
- 99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green, Liver Elasticity
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Royal North Shore Hospital
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Primary Liver Cancer, Radiofrequency Ablation
RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial
RAMEC is a phase II, multi-center, randomized trial with a safety test. There will be a safety test to establish the safety and tolerability of Neo-MASCT treatment and assess the immune response to the treatment.The randomized…
- Conditions
- Primary Liver Cancer, Radiofrequency Ablation, Immunotherapy, Hepatectomy
- Trial name
- RAMEC (NCT03067493)
- Testing
- Neo-MASCT
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)
The study will investigate whether liver transplantation provides increased survival, low side effects and good quality of life in patients with bile duct cancer where the tumor cannot be removed by normal surgery.
- Trial name
- NCT04556214
- Testing
- Liver Transplant
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Liver Metastases, Colorectal Cancer
PrOspEctive Metastases Imaging (POEM)
This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used…
- Conditions
- Liver Metastases, Colorectal Cancer, Breast Cancer
- Trial name
- POEM (NCT07781306)
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Cancer Research Antwerp
Hepatocellular Carcinoma (HCC)
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
- Trial name
- NCT06851104
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Colorectal Cancer, Liver Metastasis
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
- Trial name
- NCT05524155
- Testing
- HAIC, Sintilimab, Regorafenib
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC - Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
- Trial name
- Neo-LENTIS (NCT07475026)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cancer
Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan.
- Trial name
- NCT03063840
- Testing
- Microwave ablation
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Malignant Liver Tumor
Deportalization, Venous Deprivation, Venous Congestion
Patients with multiple primary or secondary liver tumors have a low survival rate unless they can benefit from curative extended hepatic resections with R0 or R1 marge resection.
- Trial name
- NCT03995459
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Montpellier
Carcinoma, Hepatocellular, Chronic Hepatitis B
The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the effect of serum hepatitis B virus (HBV) DNA level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (HCCs) related with HBV.
- Trial name
- NCT00397540
- Testing
- PEIT, RFTA
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Seoul National University Hospital
Myeloid Leukemia, Precursor Myeloid Neoplasms
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
The aim of this study is to test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU…
- Conditions
- Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms
- Trial name
- NCT01779882
- Testing
- Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 3 sites in Switzerland
- Volunteers
- 72 people
- Sponsor
- University Hospital, Basel, Switzerland
Carcinoma, Hepatocellular
Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)
This phase II trial studies how effectively radiofrequency ablation prevents recurrence of hepatocellular carcinoma (HCC) in patients with easily removable tumors.
- Trial name
- NCT01669668
- Testing
- radiofrequency ablation, laparoscopy
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma
Study purpose: To evaluate the efficacy and safety of Tislelizumab in combination with advanced hepatocellular carcinoma in the real world; Study design: Non-intervention, single center, case registration, real-world study…
- Trial name
- NCT04996459
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Liver Tumor
Pediatric Hepatic Tumors
Centralized biological collection of multicentric origin, retrospective and prospective of biological samples (tissues and fluids) taken within the framework of the diagnostic and therapeutic management of children and…
- Trial name
- HEPATOBIO (NCT04274868)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.